Conatumumab (AMG 655) is a human monoclonal agonist antibody against human death receptor 5 (DR5, TRAILR2) (Kd: 1 nM for the long form of DR5, 0.8 nM for the short form of DR5). Conatumumab induces apoptosis via caspase activation. Conatumumab can be used in the research of cancers. .
Conatumumab (0-10 μg/mL, 4 h) activates caspase-3/7 in Colo205, H-2122, and MiaPaCa2 cells[2].Conatumumab (0-10 μg/mL, 24 h) reduces cell viability in sensitive tumor cell lines (Colo205, H-2122, and MiaPaCa2 cells)[2].
Conatumumab (0-100 μg, i.p., twice weekly) inhibits tumor growth in mice bearing Colo205, H2122, or MiaPaCa2/T2 xenograft tumors[2].Conatumumab (2.5 μg, i.p., three times per week) enhances the antitumor activity of chemotherapeutics (CPT11, ) (80 mg/kg) in Colo 205 xenograft[2].
References:
[1]. Herbst RS, et al. A first-in-human study of conatumumab in adult patients with advanced solid tumors. Clin Cancer Res. 2010 Dec 1;16(23):5883-91.
[2]. Kaplan-Lefko PJ, et al. Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types. Cancer Biol Ther. 2010 Apr 15;9(8):618-31.